Regeneron Pharmaceuticals
Regeneron Pharmaceuticals/ US75886F1075 /
REGN
|
2024-11-07 9:59:58 PM
|
Chg.
+7.44
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
824.01USD
|
+0.91%
|
29,260
Turnover: 24.11 mill. |
-Bid Size: - |
-Ask Size: - |
90.6 bill.USD |
- |
22.25 |
Business description
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Management board & Supervisory board
| CEO |
| Dr. Leonard S. Schleifer |
| Management board |
| Robert E. Landry, Dr. George D. Yancopoulos |
| Supervisory board |
| Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D. |
Company data
| Name: |
Regeneron Pharmaceuticals Inc. |
| Address: |
777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA |
| Phone: |
+1-914-847-7000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
is.gd/sEAmh8 |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
68.40% |
| IPO date: |
1991-04-12 |
Main Shareholders
| Others |
|
50.26% |
| FMR LLC. |
|
9.52% |
| Vanguard Group |
|
8.16% |
| BlackRock Inc. |
|
7.96% |
| JP Morgan Chase & Co. |
|
6.67% |
| Capital World Investors |
|
4.73% |
| State Street Corporation |
|
4.52% |
| Capital International Investors |
|
2.69% |
| Dodge & Cox |
|
2.18% |
| Others |
|
3.30% |
